After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on a range of strategic options. | The company's board of directors ...
NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential ...
GlobalData on MSN13d
Sage rejects Biogen’s $469m takeover bidSage’s board of directors said that the proposal “significantly undervalues” the company and is not in the best interest of ...
Cambridge, USA-based biotech Sage Therapeutics yesterday announced that, while rejecting an unsolicited takeover offer, its ...
Sage Therapeutics has brought a lawsuit against ... to with Biogen,” a Sage spokesperson said in a statement to Fierce Pharma. The two firms joined hands in late 2020 when Biogen signed on ...
Since then, Biogen decided to opt out of their partnership on essential tremor candidate SAGE-324 after disappointing results ...
Sage Therapeutics has a unique approach to targeting ... there’s a trend of recent CNS drugs being acquired by other big pharma companies in the sector. It could also be simply that BIIB saw ...
Sage Therapeutics announced its boards unanimous rejection of Biogens $469 million acquisition offer, stating the proposal ...
Anti-abortion groups aren’t lobbying against RFK Jr., U.S. reported first case of H5N9 bird flu strain, Sage Therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback